Implementing a Context-Augmented Large Language Model to Guide Precision Cancer Medicine

The rapid expansion of molecularly informed therapies in oncology, coupled with evolving regulatory FDA approvals, poses a challenge for oncologists seeking to integrate precision cancer medicine into patient care. Large Language Models (LLMs) have demonstrated potential for clinical applications, but their reliance on general knowledge limits their ability to provide up-to-date and niche treatment recommendations. To address this challenge, we developed a RAG-LLM workflow augmented with Molecular Oncology Almanac (MOAlmanac), a curated precision oncology knowledge resource, and evaluated this approach relative to alternative frameworks (i.e. LLM-only) in making biomarker-driven treatment recommendations using both unstructured and structured data. We evaluated performance across 234 therapy-biomarker relationships. Finally, we assessed real-world applicability of the workflow by testing it on actual queries from practicing oncologists. While LLM-only achieved 62-75% accuracy in biomarker-driven treatment recommendations, RAG-LLM achieved 79-91% accuracy with an unstructured database and 94-95% accuracy with a structured database. In addition to accuracy, structured context augmentation significantly increased precision (49% to 80%) and F1-score (57% to 84%) compared to unstructured data augmentation. In queries provided by practicing oncologists, RAG-LLM achieved 81-90% accuracy. These findings demonstrate that the RAG-LLM framework effectively delivers precise and reliable FDA-approved precision oncology therapy recommendations grounded in individualized clinical data, and highlight the importance of integrating a well-curated, structured knowledge base in this process. While our RAG-LLM approach significantly improved accuracy compared to standard LLMs, further efforts will enhance the generation of reliable responses for ambiguous or unsupported clinical scenarios.